Ico Therapeutics Company Profile (OTCMKTS:ICOTF)

About Ico Therapeutics (OTCMKTS:ICOTF)

Ico Therapeutics logoiCo Therapeutics Inc. (iCo) is a Canada-based biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat sight-and life-threatening diseases. The Company principally focuses on in-licensing drug candidates with a clinical history, and re-dose, reformulate and develop drug candidates for the treatment of sight-and life-threatening diseases. The Company's product candidates include iCo-007, iCo-008 and an Oral AmpB Delivery System. The Company has initiated Phase II clinical trial for iCo-007. iCo-008 is a human monoclonal antibody that is offered to treat sight threatening forms of allergic conjunctivitis by neutralizing eotaxin-1, a ligand to the chemokine receptor CCR3. Oral AmpB Delivery System is a toxic option for the treatment of serious systemic fungal infections. The Company has completed pre-clinical studies for iCo's Oral AmpB Delivery System.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $3.38 million
  • Outstanding Shares: 84,457,000
Average Prices:
  • 50 Day Moving Avg: $0.04
  • 200 Day Moving Avg: $0.03
  • 52 Week Range: $0.02 - $0.07
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.02 per share
  • Price / Book: 2.00
Profitability:
  • EBIDTA: ($778,499.00)
  • Return on Equity: -42.31%
  • Return on Assets: -39.59%
Debt:
  • Current Ratio: 8.63%
  • Quick Ratio: 8.63%
Misc:
  • Average Volume: 6,776 shs.
  • Beta: 2.37
 
Frequently Asked Questions for Ico Therapeutics (OTCMKTS:ICOTF)

What is Ico Therapeutics' stock symbol?

Ico Therapeutics trades on the OTCMKTS under the ticker symbol "ICOTF."

How were Ico Therapeutics' earnings last quarter?

Ico Therapeutics Inc. (OTCMKTS:ICOTF) issued its earnings results on Wednesday, November, 27th. The company reported ($0.01) EPS for the quarter. View Ico Therapeutics' Earnings History.

Who are some of Ico Therapeutics' key competitors?

Who are Ico Therapeutics' key executives?

Ico Therapeutics' management team includes the folowing people:

  • William W. Jarosz J.D., Independent Chairman of the Board
  • Andrew J. Rae, President, Chief Executive Officer, Director
  • W. John Meekison, Chief Financial Officer, Corporate Secretary
  • Peter Hnik M.D., Chief Medical Officer
  • Richard William Barker, Independent Director
  • Noel F. Hall, Independent Director
  • Douglas Glen Janzen, Independent Director

How do I buy Ico Therapeutics stock?

Shares of Ico Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ico Therapeutics' stock price today?

One share of Ico Therapeutics stock can currently be purchased for approximately $0.04.


MarketBeat Community Rating for Ico Therapeutics (OTCMKTS ICOTF)
Community Ranking:  3.0 out of 5 (  )
Outperform Votes:  3 (Vote Outperform)
Underperform Votes:  2 (Vote Underperform)
Total Votes:  5
MarketBeat's community ratings are surveys of what our community members think about Ico Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ico Therapeutics (OTCMKTS:ICOTF) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Ico Therapeutics (OTCMKTS:ICOTF)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Ico Therapeutics (OTCMKTS:ICOTF)
Earnings by Quarter for Ico Therapeutics (OTCMKTS:ICOTF)
Earnings History by Quarter for Ico Therapeutics (OTCMKTS ICOTF)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/29/2014Q1 2014($0.02)($0.01)ViewN/AView Earnings Details
4/24/2014Q4 2013($0.02)($0.02)ViewN/AView Earnings Details
11/27/2013Q3($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ico Therapeutics (OTCMKTS:ICOTF)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Ico Therapeutics (OTCMKTS:ICOTF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ico Therapeutics (OTCMKTS:ICOTF)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Ico Therapeutics (OTCMKTS:ICOTF)
Latest Headlines for Ico Therapeutics (OTCMKTS:ICOTF)
Source:
DateHeadline
finance.yahoo.com logoiCo Therapeutics Announces Election of Directors
finance.yahoo.com - June 30 at 7:51 PM
finance.yahoo.com logoiCo Therapeutics Announces Pre IND meeting for Novel Glaucoma Asset
finance.yahoo.com - June 15 at 8:13 PM
finance.yahoo.com logoiCo Therapeutics Announces Positive Oral Amphotericin Study
finance.yahoo.com - June 12 at 6:27 PM
finance.yahoo.com logoiCo Therapeutics Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 24 at 10:44 PM
finance.yahoo.com logoIco Therapeutics posts 1Q loss
finance.yahoo.com - May 24 at 10:44 PM
finance.yahoo.com logoiCo Therapeutics Announces Year End 2016 Financial Results
finance.yahoo.com - April 19 at 10:44 PM
finance.yahoo.com logoiCo Therapeutics Inc. Announces No Material Change
finance.yahoo.com - March 13 at 5:42 PM
finance.yahoo.com logoiCo Therapeutics Provides Multiple Corporate Updates
finance.yahoo.com - January 23 at 10:56 AM
finance.yahoo.com logoiCo Therapeutics Announces Positive Study Results and Significant Advances Related to Oral Amphotericin B Program
finance.yahoo.com - November 29 at 4:39 PM
finance.yahoo.com logoCLARIFICATION: iCo Therapeutics Announces Positive Study Results and Significant Advances Related to Oral Amphotericin B Program
finance.yahoo.com - November 29 at 4:39 PM
finance.yahoo.com logoiCo Therapeutics Announces Third Quarter 2016 Financial Results
finance.yahoo.com - November 24 at 8:37 AM
finance.yahoo.com logoiCo Therapeutics Announces World Wide Exclusive Option and EU License Rights with Laboratorios SALVAT for Novel Glaucoma Asset
finance.yahoo.com - November 15 at 11:37 AM
finance.yahoo.com logoiCo Therapeutics Announces Voting and Election Results from Annual Meeting of Shareholders
finance.yahoo.com - June 27 at 4:46 PM
finance.yahoo.com logoICO THERAPEUTICS INC Financials
finance.yahoo.com - June 8 at 1:04 PM

Social

Chart

Ico Therapeutics (ICOTF) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by MarketBeat.com Staff